TCWP’s Novo Nordisk NVO Stock Holding History

TCWP’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-886	Closed	-$49K	–	1240
2022 Q1	$49K	Buy	+886	New	+$45.5K	0.01%	482

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCWP's NVO Position: Q2 2022 in Review

TCWP sold out of Novo Nordisk (NVO) in Q2 2022, closing a stake of 886 shares — an estimated $49K sold.

TCWP first reported a position in NVO in Q1 2022 and held it in 1 quarter. The position peaked at $49K in Q1 2022. 933 funds tracked by Wall St. Rank hold NVO as of Q2 2022.

TCWP reported no remaining Novo Nordisk position as of Q2 2022 after selling out during the quarter.
TCWP sold 886 Novo Nordisk shares in Q2 2022, an estimated $49K.
TCWP first reported a position in Novo Nordisk in Q1 2022 and held it in 1 quarter.
TCWP's Novo Nordisk position peaked at $49K in Q1 2022.
933 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.